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Abstract
AIM: To evaluate the prophylactic properties of integrin 
CD18-βA peptide in a murine model of abdominal poly-
microbial peritonitis and sepsis. 
METHODS: Bacterial sepsis was induced in Institute of 
Cancer Research (ICR) mice by cecal ligation and punc-
ture (CLP) surgery. Inflicted mice were then injected 
with either sterile saline or CD18-βA peptide intraperi-
toneally at 2 h after surgery, and were sacrificed at 12 
and 24 h after surgery. Blood samples were immediately 
collected, and analyzed for endotoxin activity and tumor 
necrosis factor (TNF)-α and interleukin (IL)-6. Lungs 
and liver were studied for CD45+ leukocyte and CD3 
mRNA content. Pulmonary expression of intercellular 
adhesion molecule (ICAM)-1, vascular cell adhesion 
molecule (VCAM) and E-selectin was also determined.
RESULTS: Intraperitoneal injection of CD18-βA peptide 
significantly suppressed circulating endotoxin activity (P 
< 0.01) at 24 h, as well as serum levels of TNF-α (P  < 
0.05 at 12 and 24 h) and IL-6 (P < 0.01 at 12 h, P < 0.05 
at 24 h) in CLP-inflicted mice. CD18-βA peptide also 
abrogated leukocyte infiltration into liver and lungs as 
unveiled by reduced CD45+ leukocyte and CD3 mRNA 
contents. Furthermore, the peptide significantly re-
duced pulmonary expression of VCAM (P < 0.01 at 12 h, 
P  < 0.001 at 24 h), E-selectin (P  < 0.01 at 12 and 24 h), 
and ICAM-1 (P  < 0.01 at 12 h, P  < 0.001 at 24 h). 
These actions of CD18-βA peptide collectively protected 
septic mice against lethality (P  < 0.01). 
CONCLUSION: CD18-βA peptide is a potent endotox-
in antagonist that can protect surgical patients against 
sepsis-associated lethality.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Endotoxin [or lipopolysaccharide (LPS)] was first identi-
fied by Richard Pfeiffer from the late log phase culture 
of  Vibrio cholerae, of  which the heat inactivated bacterial 
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lysates could induce septic shock and death in experimen-
tal animals[1,2]. In clinical settings, circulating endotoxin 
acts as a pivotal initiator in the pathogenesis of  bacterial 
sepsis and signals front-line immune host cells to trigger 
the “cytokine storm”, resulting in systemic inflammatory 
response syndrome (SIRS)[3]. Given that the deleteri-
ous SIRS goes unchecked, patients may develop and die 
from acute respiratory distress, shock, and multiple organ 
dysfunction. Severely ill patients in surgical wards and in-
tensive care units are at risk from sepsis-associated death, 
despite the use of  broad-spectrum antibiotics, cortico-
steroids, and other new drugs like drotrecogin alfa[4]. To 
resolve the stringent clinical situation, many experimental 
therapeutics like cultured bone marrow stromal cells[5], 
cholinergic agonists[6] and lysophosphatidylcholine[7] have 
emerged as potential therapeutics. Studies on their thera-
peutic efficacies however still remain in pre-clinical stages. 
Our previous finding has identified that leukocyte 
integrin CD18 βA peptide is able to bind bacterial LPS 
and to alleviate the pro-inflammatory responses in LPS-
stimulated Jurkat cells[8]. In the present study, we evalu-
ated the potential prophylactic use of  CD18-βA peptide 
in a murine model of  cecal ligation and puncture (CLP) 
that resembles abdominal polymicrobial peritonitis and 
sepsis in humans[9].
MATERIALS AND METHODS
CD18-βA peptide
We designed the CD18-βA peptide basing on the residues 
266-318 of  CD18 of  leukocyte β2 integrins. We cloned 
the cDNA fragment into pET43.1B vector (Novagen, San 
Diego, CA, USA), expressed recombinant CD18-βA pep-
tide in E. coli. BL21 (DE3) (Novagen), and subsequently 
purified the resulting protein using ion mobilized affinity 
chromatography following our published procedure[8,10]. 
Before we injected CD18-βA peptide into mice, we dia-
lyzed the peptide against sterile phosphate buffered saline. 
We verified the purity using electrophoresis, and measured 
the concentration of  CD18-βA peptide as described[11].
Polymicrobial CLP peritonitis model in mice
We obtained male Institute of  Cancer Research (ICR) 
mice (30 g in weight) from the AAALAC-accredited 
Laboratory Animal Unit of  the University of  Hong Kong 
(Pokfulam, Hong Kong), and divided them randomly into 
three experimental groups of  equal size. We then main-
tained all mice in a vivarium on a 12-h light/dark cycle 
at 21℃. Mice had ad libitum access to a sterilized animal 
chow and water. We performed all experimental proce-
dures on mice in accordance with the ethical guidelines set 
forth by the University’s Committee on Using Live Ani-
mals for Teaching and Research. 
We performed CLP as previously described[5] in ICR 
mice. We anaesthetized mice with an intraperitoneal injec-
tion of  50 mg/kg sodium pentobarbital (Nembutal, Rhone 
Merieux, Pinkenba, QLD, Australia), and opened the ante-
rior abdomen by a 15 mm midline incision. Afterwards, we 
ligated the exposed cecum non-obstructively with surgical 
silk, punctured it twice with a 19-gauge needle, and then 
replaced it back to the peritoneal cavity. For sham-oper-
ated mice, we opened the abdomen, but the cecum was 
neither ligated nor punctured. Finally, we completed CLP 
surgery by closing the abdomen wall with nylon sutures, 
and gave no analgesics and antibiotics to mice. At 2 h 
after the completion of  CLP surgery, we injected 0.1 mL 
sterile saline intraperitoneally into 12 mice, and 0.8 mg/kg 
CD18-βA peptide (this optimal dosage was prior deter-
mined in a pilot study ranging from 0.6-1.2 mg/kg) to an-
other 12 mice. An additional injection of  sterile saline or 
CD18-βA peptide, respectively, was given to mice at 14 h 
after the completion of  CLP surgery. We gave no treat-
ment to the sham-operated mice throughout the experi-
ment. We killed six mice from each of  the three experi-
mental groups at 12 and 24 h after CLP. Therefore, mice 
that were sacrificed at 12 and 24 h received one and two 
injections of  CD18-βA peptide, respectively. We collected 
blood from the interior vena cava, and harvested lung 
and liver. We obtained serum from the collected blood by 
centrifugation at 3000 rpm for 10 min at 4℃. For each 
harvested lung and liver, we minced it into two pieces that 
were formalin-fixed and snap-frozen separately. 
Survival study
We studied the survival of  septic mice receiving different 
treatments after CLP in another group of  ICR mice (n = 
8 in each experimental group, in total 24 mice). We per-
formed CLP as previously described, and injected mice 
intraperitoneally with either sterile saline or CD18-βA 
peptide at 2, 12 and 24 h after closure of  abdomen. Ster-
ile saline was used as a control according to our earlier 
studies and reported procedures[5,7,12]. We assessed sur-
vival after CLP continually for 48 h, and regarded mice 
that still remained alive beyond the observation period as 
survivors. Survival data were analyzed using the Kaplan-
Meier module in GraphPad Prism (GraphPad Software 
Inc., La Jolla, CA, USA).
Limulus amoebocyte lysate assay of endotoxin activity
We determined the endotoxin activity in circulation us-
ing the Limulus amoebocyte lysate (LAL) pyrochrome 
kit (Associates of  Cape Cod Inc, East Falmouth, MA, 
USA) as previously described[13,14]. All buffers for the 
LAL assay were prepared using endotoxin-free water ac-
cording to manufacturer’s instructions. We measured the 
resulting signal spectrophotometrically at 540 nm using 
a microtiter plate reader (Molecular Devices, Sunny-
vale, CA, USA), and each sample was done in triplicate. 
We finally determined the endotoxin activity from the 
measured signals using a standard curve with a dynamic 
range from 0 to 0.623 Endotoxin Units (EU)/mL.
Tumor necrosis factor-α and interleukin-6 enzyme-
linked immunosorbent assay
We measured the serum level of  tumor necrosis factor 
(TNF)-α and interleukin (IL)-6 of  mice using commer-
cially available enzyme-linked immunosorbent assay kits 
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that were purchased from Dakewe (Shenzhen, China) 
and eBioscience (San Diego, CA, USA), respectively, in 
accordance with instructions previously reported[15,16].
Immunohistochemistry
We followed our published procedures to perform all immu-
nohistochemical staining[17,18]. To study the CD45+ leuko-
cyte content in lungs and liver of  mice, we stained tissue par-
affin sections with 10 μg/mL monoclonal antibody against 
CD45 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
as described[19]. We stained lung tissues with 20 μg/mL 
monoclonal antibody against VCAM (20 μg/mL; BD 
Biosciences, San Jose, CA, USA) and 20 μg/mL monoclo-
nal antibody against E-selectin (BD Biosciences) to study 
pulmonary expression of  the two adhesion molecules. We 
incubated tissue sections with respective antibodies at 4℃ 
overnight. After washing, we added a horseradish perox-
idase-conjugated secondary antibody (Invitrogen, Carls-
bad, CA, USA). We visualized the resulting signals with a 
liquid DAB substrate kit (Invitrogen), and thereafter, we 
counterstained tissue sections with hematoxylin (Vector 
Laboratories, Burlingame, CA, USA). 
Real-time polymerase chain reaction
We measured the level of  CD3 mRNA in lung and liver 
of  mice after CLP using real-time polymerase chain reac-
tion (PCR). This method provides robust and quantitative 
measurement on tissue infiltration of  inflammatory leuko-
cytes[20]. To study the expression of  ICAM-1, VCAM, and 
E-selectin in lungs, we measured their mRNA levels. We 
performed RNA extraction, first-strand cDNA synthesis, 
and real-time PCR in ABI PRISM 7700 sequence detector 
system (Applied Biosystems Inc., Forest Hill, CA, USA) as 
previously described[21-23].
Statistical analysis 
We performed all statistical analysis using the GraphPad 
Prism (GraphPad Software Inc.); group means of  the 
study parameters were compared by one-way ANOVA, 
and P values < 0.05 were considered to indicate statisti-
cal significance. 
RESULTS
Survival of septic mice
Diagnosis of  bacterial sepsis in most clinical scenarios is 
always delayed, therefore in this study we injected mice 
intraperitoneally with CD18-βA peptide (0.8 mg/kg) (or 
sterile saline) at 12-h intervals beginning two hours after 
the CLP surgery. We first looked at the survival rates af-
ter CLP surgery in saline- and CD18-βA peptide-treated 
mice. A statistically significant (P < 0.01) improvement 
in the survival of  mice injected CD18-βA peptide in-
traperitoneally was noted (Figure 1A); about 40% of  
mice survived over the 48 h post-operative observation 
period, and remained alive thereafter despite discontinu-
ation of  therapy. In contrast, mice that received saline all 
died within the 36 post-operative hour period.
Endotoxicity and pro-inflammatory cytokines in 
circulation
We next investigated whether the beneficial effect of  
CD18-βA peptide on the survival of  septic mice was as-
sociated with reductions in endotoxin activity in circula-
tion. To this end, we measured both biological activity 
of  endotoxin and serum levels of  TNF-α and IL-6 after 
we sacrificed mice at 12 and 24 h after CLP surgery and 
collected blood samples at the interior vena cava. Mice 
inflicted with CLP surgery showed up-regulation of  the 
circulating endotoxin activity and TNF-α and IL-6 levels 
in serum samples, which could be remarkably modulated 
by treatment with CD18-βA peptide but not with saline 
control (Figure 1B). Intraperitoneal injection of  CD18-
βA peptide achieved a statistically significant reduction 
in circulating endotoxin activity (P < 0.01) at 24 h, as 
well as serum levels of  TNF-α (P < 0.05 at 12 and 24 h) 
and IL-6 (P < 0.01 at 12 h, P < 0.05 at 24 h). 
CD45+ leukocyte and CD3 mRNA contents in lungs and 
liver
In view of  the fact that infiltrating leukocytes usually 
injure tissues, we first studied histologically the effect of  
CD18-βA peptide on CD45+ leukocyte infiltration in 
lungs and liver of  septic mice (Figure 2A). Intense CD45 
reactivity was detected in the lungs and liver organs from 
the placebo group. Strikingly, a bolus of  CD18-βA pep-
tide injection drastically diminished CD45+ cells in liver, 
and almost completely eradicated the CD45+ signals in 
lungs. Further to confirm this observation, we measured 
the level of  CD3 mRNA that is expressed by infiltrating 
leukocytes using real-time PCR (Figure 2B). Compared 
to the sham control, CD3 mRNA levels of  lungs and 
liver were up-regulated by over 10-20 fold by CLP sur-
gery, and these elevations were reduced significantly by 
treatment with the CD18-βA peptide (P < 0.05). Taken 
together, we suggest that CD18-βA peptide can be used 
to prevent leukocyte infiltration in bacterial sepsis. 
ICAM-1, VCAM and E-selectin expression in lungs
Adhesion molecules facilitate leukocyte trafficking, and 
are implicated in mediating organ injuries[24]. To study 
the effect of  CD18-βA peptide on adhesion molecule 
expression, we first determined the pulmonary expres-
sion of  VCAM and E-selectin by immunohistochemistry 
(Figure 2C). Intense immunoreactivity toward VCAM 
and E-selectin was detected in lung paraffin sections pre-
pared from saline-treated septic mice, whereas the corre-
sponding immunoreactivities were markedly diminished 
from the CD18-βA peptide-treated mice. Expression of  
ICAM-1, VCAM, and E-selectin mRNA in lungs has also 
been determined by real-time PCR. Similarly, mRNA 
levels of  the three adhesion molecules surged in lungs 
of  saline-treated septic mice, whereas such elevations 
were significantly suppressed after CD18-βA peptide 
treatment: VCAM (P < 0.01 at 12 h, P < 0.001 at 24 h), 
E-selectin (P < 0.01 at 12 and 24 h), and ICAM-1 (P < 
0.01 at 12 h, P < 0.001 at 24 h) (Figure 2C).
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DISCUSSION
We illustrated in a stringent murine model of  bacterial 
sepsis that CD18-βA peptide was able to neutralize cir-
culating endotoxin, to reduce serum TNF-α and IL-6 
levels, to inhibit leukocyte infiltrating into lungs and 
liver, and to suppress endotoxin-induced adhesion mol-
ecule expression. All these protective actions of  CD18-
βA peptide might contribute to survival benefits of  the 
animals in the sepsis model. 
We found the protection of  CD18-βA peptide on 
septic mice was in some ways impressive. Notably, CD18-
βA peptide still afforded protection on septic mice even 
when it was administered after onset of  bacterial sepsis. 
This is in contrast to many other therapeutic interventions 
that are incapable of  halting the already-initiated super-
inflammatory responses in surgical patients. In view of  
this, CD18-βA peptide can serve as an adjunctive thera-
peutic particularly for patients who are being challenged 
by high concentration of  endotoxin, which usually results 
with a delayed diagnosis of  bacterial sepsis. One of  the 
possible underlying mechanisms for the effective endo-
toxin neutralization could be attributed to the presence of  
an amphipathic helix motif  (VGQLAHKLAENNIQPI-
FA) at the C-terminal end (Figure 3). Such structural 
moiety favors endotoxin binding and neutralization of  
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Figure 1  CD18-βA peptide protects mice against cecal ligation and puncture (CLP)-induced lethality and inflammatory responses. A: Mice were injected with 
either sterile saline or CD18-βA peptide intraperitoneally at 12 h intervals beginning 2 h after CLP (as indicated by arrows), and were monitored continually over 48 h. 
There was statistically significant improvement in survival of septic shock mice that received CD18-βA injection (P < 0.01), compared to those that received saline. n = 
8 for each experimental groups; B: Measurement of endotoxin activity and tumor necrosis factor (TNF)-α and interleukin (IL)-6 levels in blood circulation. Injection of 
CD18-βA peptide achieved significant reductions in endotoxin activity at 24 h, and reductions in TNF-α and IL-6 at 12 and 24 h after CLP. 12 h, n = 5 and 24 h, n = 6 
for each experimental group. aP < 0.05, bP < 0.01 vs saline group (one-way ANOVA). Error bars represent mean ± SD.
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endotoxicity[25]. In addition, we have previously shown 
that the positively charged residues (e.g. arginine, lysine) 
along the CD18-βA peptide are contributing to the effec-
tive binding to LPS of  various bacterial strains[8]. 
We showed CD18-βA peptide is an effective agent to 
suppress the “cytokine storm” in bacterial sepsis, given 
that the peptide significantly reduced TNF-α and IL-6 
levels in the circulation of  septic mice. This aspect of  
CD18-βA peptide is essential to sepsis treatment because 
pro-inflammatory cytokines can stimulate phagocytes to 
release reactive oxygen species, increasing vascular perme-
ability and leading to organ injury[26]. In fact, therapeutic 
agents like anti-cytokine antibodies and receptor antago-
nists that are aiming to abolish cytokine functions have 
long been developed. Unfortunately, none of  these agents 
proved efficacious in protecting sepsis patients[27,28], appar-
ently because of  the redundancy of  cytokine functions. 
Unlike these therapeutic agents, use of  CD18-βA peptide 
can circumvent this problem because in our recent study, 
we have shown CD18-βA peptide could down-modulate 
the NF-κB-mediated signaling that is central to the release 
of  many pro-inflammatory cytokines. 
The clinical utility of  CD18-βA peptide as a sepsis 
therapeutic is further enhanced by its ability to inhibit 
leukocyte infiltration into lungs and liver, given that 
leukocyte-mediated injury on these two organs cause the 
high mortality rate of  sepsis patients[29,30]. The inhibi-
tion is likely attributed to the suppression of  adhesion 
molecules in lungs. In addition to this mechanism, it was 
apparent that CD18-βA peptide could block the integ-
rin binding sites on adhesion molecules (e.g. ICAM-1) 
because CD18-βA peptide is homologous to the CD18 
antigen of  leukocyte β2 integrins. Indeed, this hypoth-
esis is supported by our early study showing that a re-
combinant CD18 subunit could inhibit the binding of  
leukocytes to immobilized adhesion molecules (Luk JM, 
unpublished observation). We also hypothesized that 
CD18-βA peptide could antagonize direct activation of  
leukocytes by bacterial endotoxin as our recent study has 
illustrated that CD18-βA peptide could prevent the sens-
ing of  Jurkat cells by bacterial LPS in vitro[8].
Furthermore, a recent in vivo animal study of  nec-
rotizing enterocolitis has readily demonstrated the po-
tential therapeutic efficacy of  CD18-βA peptide against 
LPS-induced proinflammatory reactions[31]. In that study, 
rat intestine was distended and then challenged by bacte-
rial LPS, culminating in profound TNF-α release from 
immune cells, intense leukocyte influx into the intestine, 
and severe intestinal tissue damage. CD18-βA peptide 
was able to neutralize the LPS endotoxicity and modu-
late the above-mentioned deleterious immune responses. 
In summary, CD18-βA peptide is a promising thera-
peutic for intervention of  bacterial sepsis. Unlike anti-LPS 
antibodies that failed to protect septic patients because of  
their inability to inhibit pro-inflammatory cytokine releas-
es from immune cells[32], CD18-βA peptide can halt the 
deleterious “cytokine storm” in bacterial sepsis. To further 
assess the therapeutic efficacy of  CD18-βA peptide, we 
are going to study the protective action in a porcine model 
of  endotoxemia[33]. 
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Figure 2  CD18-βA peptide inhibits CD45+ leukocyte infiltration into lung and liver in CLP-induced mice. A: CD45+ leukocyte content in lung and liver after 
CLP was visualized by immunohistochemistry. Images are representative of n = 6 for each experimental group. Scale bar, 80 μmol/L; B: Real-time polymerase chain 
reaction (PCR) analysis of CD3 mRNA level in lungs and liver, normalized to β-actin, at 12 and 24 h after CLP. Significant reductions in CD3 mRNA contents were 
observed in lungs and liver of septic mice that have been treated with CD18-βA peptide. aP < 0.05 vs saline group (one-way ANOVA); C: Pulmonary expression of 
adhesion molecules was studied using immunohistochemistry and real-time PCR. Lung sections were stained with VCAM and E-selectin antibody, and images are 
representative of n = 6 for each experimental group. Scale bars, 80 μm. Real-time PCR was employed to study mRNA expression of ICAM-1, VCAM, and E-selectin 
in lungs. Significant reductions in adhesion molecule mRNA contents were observed in lungs of septic mice that were treated with CD18-βA peptide. bP < 0.01, dP < 
0.001 vs saline group (one-way ANOVA). For all real-time PCR study, n = 6 for each experimental group at 12 and 24 h. Error bars represent mean ± SD. 
Figure 3  A predicted model of the amphipathic helix sequence at CD18-
βA that binds bacterial endotoxin. Shown is the polypeptide sequence of 
the CD18-βA domain of leukocyte β2 integrin, and the two LPS-binding sites 
are colored green and red. CD18-βA peptide is derived from the red binding 
site. The underlined portion of CD18-βA peptide demonstrates a feature of the 
amphipathic helix, as revealed by the helical wheel diagram.
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CD18-βA domain
for critical review and professional editing of  the manu-
script. The use of  CD18-βA peptide in treating sepsis 
has been filed for US patent (application 61/080,558) and 
PCT Patent Application No. PCT/CN2009/000791. 
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Background
Patients severely infected with Gram-negative bacteria can die of endotoxemia 
and sepsis. Indeed, despite the emergence of broad-spectrum antibiotics, cortico-
steroids, and advanced surgical resuscitative supports, sepsis remains one of the 
leading causes of death in intensive care units. In this context, many experimental 
therapeutic agents have been developed over the last few decades. Disappoint-
ingly, only a few of these agents were shown to improve survival, and nearly none 
of them could halt the unchecked inflammatory response of sepsis. 
Research frontiers
CD18-βA peptide is a novel endotoxin antagonistic peptide derived from a lipo-
polysaccharide (LPS)-binding site of leukocyte integrins, and was found able to 
suppress the stimulation of LPS on leukocytes in vitro. The present work is the 
first published data concerning the use of CD18-βA peptide in the treatment of 
mice with polymicrobial peritonitis. 
Innovations and breakthroughs
The key pathogenesis of sepsis is the super-inflammatory response (or “cyto-
kines storm”) that can ultimately lead to multiple organ failure and inevitably 
death. To date, clinical uses of corticosteroids and antibiotics, and experimental 
uses of cytokine antibodies all fail to halt the deleterious immunological cas-
cades. In this study, CD18-βA peptide was shown to antagonize endotoxicity 
in circulation, preventing the pro-inflammatory “cytokines storm” from initiation. 
This mitigation of the inflammatory response reduced the influx of leukocytes 
from the bloodstream into lungs and liver, protecting both organs from leuko-
cyte-mediated damage. All these beneficial effects of CD18-βA peptide collec-
tively protected septic mice against death. 
Applications 
The indication of CD18-βA peptide as a potent endotoxin antagonist promises 
to be an effective therapeutic agent to alleviate the deleterious superinflamma-
tory responses in patients with acute septic conditions. 
Terminology
Polymicrobial peritonitis model is a clinically relevant model that resembles sep-
sis resulting from endotoxemia. Endotoxin (e.g. LPS) is a structural component 
of the Gram-negative bacteria cell wall, and once been liberated to circulation, 
can stimulate the innate immunity to release pro-inflammatory cytokines, culmi-
nating in systemic inflammatory response syndrome and sepsis. 
Peer review
This is a paper that evaluates the prophylactic properties of integrin CD18, and 
the results are very important. The authors show integrin CD18 suppressed circu-
lating endotoxin activity and levels of tumor necrosis factor-α and interleukin-6. 
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